EUVIMEDEUVIMED entdecken
Open Access

Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease

A-Na Liu, Cui-Fang Xu, Ya-Ru Liu, Dan-Qin Sun, Ling Jiang, Liang-Jie Tang, Pei-Wu Zhu, Sui-Dan Chen, Wen-Yue Liu, Xiao-Dong Wang, Giovanni Targher iD, Christopher D Byrne und 6 weitere

Alimentary Pharmacology & Therapeutics · 2023-04 · 57 (8) · 872-885

DOI: 10.1111/apt.17362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 20.01.2023. Verfasst von A-Na Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Child Health, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIAAA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dysregulated bile acid (BA) metabolism has been linked to steatosis, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD).

Aim

To determine whether circulating BA levels accurately stage liver fibrosis in NAFLD.

Methods

We recruited 550 Chinese adults with biopsy‐proven NAFLD and varying levels of fibrosis. Ultra‐performance liquid chromatography coupled with tandem mass spectrometry was performed to quantify 38 serum BAs.

Results

Compared to those without fibrosis, patients with mild fibrosis (stage F1) had significantly higher levels of secondary BAs, and increased diastolic blood pressure (DBP), alanine aminotransferase (ALT), body mass index, and waist circumstance (WC). The combination of serum BAs with WC, DBP, ALT, or Homeostatic Model Assessment for Insulin Resistance performed well in identifying mild fibrosis, in men and women, and in those with/without obesity, with AUROCs 0.80, 0.88, 0.75 and 0.78 in the training set ( n = 385), and 0.69, 0.80, 0.61 and 0.69 in the testing set ( n = 165), respectively. In comparison, the combination of BAs and clinical/biochemical biomarkers performed less well in identifying significant fibrosis (F2‐4). In women and in non‐obese subjects, AUROCs were 0.75 and 0.71 in the training set, 0.65 and 0.66 in the validation set, respectively. However, these AUROCs were higher than those observed for the fibrosis‐4 index, NAFLD fibrosis score, and Hepamet fibrosis score.

Conclusions

Secondary BA levels were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum BAs and clinical/biochemical biomarkers for identifying mild fibrosis merits further assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseAdultMaleHumansFemaleBile Acids and SaltsLiver CirrhosisInflammationBiomarkersObesityLiver

Stichwörter der Autor:innen

liver fibrosisnonalcoholic fatty liver diseaserisk predictionsecondary bile acids

Substanzen

Bile Acids and SaltsBiomarkers

Autor:innen und Institutionen

  • National Clinical Research Center for Child Health, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Nephrology, The Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, Wuxi, China.
  • Affiliated Wuxi Clinical College of Nantong University, Wuxi, China.
  • NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Laboratory Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

ORCID-Profile: Giovanni Targher, Vincent Wai-Sun Wong, Rohit Loomba, Ming-Hua Zheng, Yan Ni

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NIAAA NIH HHS
  • NHLBI NIH HHS
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • National Center for Advancing Translational Sciences
  • Università degli Studi di Verona

Zitieren

APA

Liu, A. N., Xu, C. F., Liu, Y. R., Sun, D. Q., Jiang, L., Tang, L. J., Zhu, P. W., Chen, S. D., Liu, W. Y., Wang, X. D., Targher, G., Byrne, C. D., Wong, V. W., Fu, J., Su, M. M., Loomba, R., Zheng, M. H., & Ni, Y. (2023). Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 57(8), 872-885. https://doi.org/10.1111/apt.17362

Vancouver

Liu AN, Xu CF, Liu YR, Sun DQ, Jiang L, Tang LJ, et al. Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 2023;57(8):872-885. doi:10.1111/apt.17362

BibTeX
@article{Liu2023,
  author = {Liu, A-Na and Xu, Cui-Fang and Liu, Ya-Ru and Sun, Dan-Qin and Jiang, Ling and Tang, Liang-Jie and Zhu, Pei-Wu and Chen, Sui-Dan and Liu, Wen-Yue and Wang, Xiao-Dong and Targher, Giovanni and Byrne, Christopher D and Wong, Vincent Wai-Sun and Fu, Junfen and Su, Ming-Ming and Loomba, Rohit and Zheng, Ming-Hua and Ni, Yan},
  title = {Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {57},
  number = {8},
  pages = {872--885},
  doi = {10.1111/apt.17362}
}
Kostenlos starten →